Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy ... 1 As Remdantry uses the same Drug Identification Number (DIN) ...

Stelara, the brand name of the drug ustekinumab, is a popular treatment for plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. The FDA defines a biosimilar as a ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly ...

FDA commissioner Scott Gottlieb said: “Bringing new biosimilars to patients is a top priority for the FDA, and a key part of our efforts to help promote competition that can reduce drug costs an ...

As global markets grapple with ongoing trade uncertainties and recession fears, major indices like the S&P 500 and Dow Jones Industrial Average have seen consecutive weeks of negative returns. Amidst ...